* pregnancy or puerperium * having received any other covid-19 vaccine any time before inclusion in the study * having received any other vaccine 30 days before inclusion in the study * covid-19 disease confirmed by rt-pcr (real time polymerase chain reaction) up to 28 days before inclusion in the study. * covid-19 symptoms during evaluation of inclusion in the study (day 0). * fever (axillary temperature above 37,8 º c / 100,04 °f) 72 hours before vaccination in the study. * contraindications to the covid-19 (recombinante) vaccine - fiocruz/astrazeneca * use of immunosuppressive medication, such as systemic corticosteroids or chemotherapy, or immunosuppressive diseases. we will consider as immunosuppressive doses of systemic corticosteroids daily doses of prednisone of 10mg or more, for more than 14 days. * any discoveries made by the principal investigator that would enhance the risk of an adverse result following the participation in the study, or that in some other way justifies exclusion from the study.

* pregnancy or puerperium * having received any other covid-19 vaccine any time before inclusion in the study * having received any other vaccine 30 days before inclusion in the study * covid-19 disease confirmed by rt-pcr (real time polymerase chain reaction) up to 28 days before inclusion in the study. * covid-19 symptoms during evaluation of inclusion in the study (day 0). * fever (axillary temperature above 37,8 º c / 100,04 °f) 72 hours before vaccination in the study. * contraindications to the covid-19 (recombinante) vaccine - fiocruz/astrazeneca * use of immunosuppressive medication, such as systemic corticosteroids or chemotherapy, or immunosuppressive diseases. we will consider as immunosuppressive doses of systemic corticosteroids daily doses of prednisone of 10mg or more, for more than 14 days. * any discoveries made by the principal investigator that would enhance the risk of an adverse result following the participation in the study, or that in some other way justifies exclusion from the study.

pregnancy or puerperium having received any other covid-19 vaccine any time before inclusion in the study having received any other vaccine 30 days before inclusion in the study covid-19 disease confirmed by rt-pcr (real time polymerase chain reaction) up to 28 days before inclusion in the study. covid-19 symptoms during evaluation of inclusion in the study (day 0). fever (axillary temperature above 37,8 º c / 100,04 °f) 72 hours before vaccination in the study. contraindications to the covid-19 (recombinante) vaccine - fiocruz/astrazeneca use of immunosuppressive medication, such as systemic corticosteroids or chemotherapy, or immunosuppressive diseases. we will consider as immunosuppressive doses of systemic corticosteroids daily doses of prednisone of 10mg or more, for more than 14 days. any discoveries made by the principal investigator that would enhance the risk of an adverse result following the participation in the study, or that in some other way justifies exclusion from the study.

pregnancy or puerperium having received any other covid-19 vaccine any time before inclusion in the study having received any other vaccine 30 days before inclusion in the study covid-19 disease confirmed by rt-pcr (real time polymerase chain reaction) up to 28 days before inclusion in the study. covid-19 symptoms during evaluation of inclusion in the study (day 0). fever (axillary temperature above 37,8 º c / 100,04 °f) 72 hours before vaccination in the study. contraindications to the covid-19 (recombinante) vaccine - fiocruz/astrazeneca use of immunosuppressive medication, such as systemic corticosteroids or chemotherapy, or immunosuppressive diseases. we will consider as immunosuppressive doses of systemic corticosteroids daily doses of prednisone of 10mg or more, for more than 14 days. any discoveries made by the principal investigator that would enhance the risk of an adverse result following the participation in the study, or that in some other way justifies exclusion from the study.